| [1] |
Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. |
| [2] |
European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021. |
| [3] |
ABAALKHAIL FA, AL-HAMOUDI WK, KHATHLAN A, et al. SASLT practice guidelines for the management of Hepatitis B virus - An update[J]. Saudi J Gastroenterol, 2021, 27(3): 115-126. DOI: 10.4103/sjg.sjg_539_20. |
| [4] |
MARTIN P, NGUYEN MH, DIETERICH DT, et al. Treatment algorithm for managing chronic hepatitis B virus infection in the United States: 2021 Update[J]. Clin Gastroenterol Hepatol, 2022, 20(8): 1766-1775. DOI: 10.1016/j.cgh.2021.07.036. |
| [5] |
HOWELL J, HELLARD M. Making child's play of tolerance: Defining the immune-viral interplay during combination entecavir and pegylated interferon therapy for immune-tolerant hepatitis B infection[J]. Hepatology, 2022, 76(3): 554-557. DOI: 10.1002/hep.32450. |
| [6] |
DUSHEIKO G, AGARWAL K, MAINI MK. New Approaches to chronic hepatitis B[J]. N Engl J Med, 2023, 388(1): 55-69. DOI: 10.1056/NEJMra2211764. |
| [7] |
|
| [8] |
BERTOLETTI A, KENNEDY PT. The immune tolerant phase of chronic HBV infection: new perspectives on an old concept[J]. Cell Mol Immunol, 2015, 12(3): 258-263. DOI: 10.1038/cmi.2014.79. |
| [9] |
MASON WS, GILL US, LITWIN S, et al. HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant[J]. Gastroenterology, 2016, 151(5): 986-998. DOI: 10.1053/j.gastro.2016.07.012. |
| [10] |
RUAN P, DAI X, SUN J, et al. Different types of viral-host junction found in HBV integration breakpoints in HBV-infected patients[J]. Mol Med Rep, 2019, 19(2): 1410-1416. DOI: 10.3892/mmr.2018.9709. |
| [11] |
KOFFAS A, KUMAR M, GILL US, et al. Chronic hepatitis B: the demise of the 'inactive carrier' phase[J]. Hepatol Int, 2021, 15(2): 290-300. DOI: 10.1007/s12072-021-10137-2. |
| [12] |
NGUYEN MH, GARCIA RT, TRINH HN, et al. Histological disease in Asian-Americans with chronic hepatitis B, high hepatitis B virus DNA, and normal alanine aminotransferase levels[J]. Am J Gastroenterol, 2009, 104(9): 2206-2213. DOI: 10.1038/ajg.2009.248. |
| [13] |
GONG X, YANG J, TANG J, et al. A mechanistic assessment of the discordance between normal serum alanine aminotransferase levels and altered liver histology in chronic hepatitis B[J]. PLoS One, 2015, 10(7): e0134532. DOI: 10.1371/journal.pone.0134532. |
| [14] |
National Health Commission of the People's Republic of China. Diagnosis for HIV/AIDS[S]. 2019-01-02.
中华人民共和国国家卫生健康委员会. 艾滋病和艾滋病毒感染诊断[S]. 2019-01-02.
|
| [15] |
CASTRO KG, WARD JW, SLUTSKER L, et al. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults[J]. MMWR Recomm Rep, 1992, 41(RR-17): 1-19.
|
| [16] |
HUI CK, LEUNG N, YUEN ST, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase[J]. Hepatology, 2007, 46(2): 395-401. DOI: 10.1002/hep.21724. |
| [17] |
MARTIN P, LAU DT, NGUYEN MH, et al. A Treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2015 Update[J]. Clin Gastroenterol Hepatol, 2015, 13(12): 2071-2087. e16. DOI: 10.1016/j.cgh.2015.07.007. |
| [18] |
TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800. |
| [19] |
SARIN SK, KUMAR M, LAU GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update[J]. Hepatol Int, 2016, 10(1): 1-98. DOI: 10.1007/s12072-015-9675-4. |
| [20] |
WESTIN J, ALEMAN S, CASTEDAL M, et al. Management of hepatitis B virus infection, updated Swedish guidelines[J]. Infect Dis (Lond), 2020, 52(1): 1-22. DOI: 10.1080/23744235.2019.1675903. |
| [21] |
ARORA A, SINGH SP, KUMAR A, et al. INASL position statements on prevention, diagnosis and management of hepatitis B virus infection in India: The Andaman Statements[J]. J Clin Exp Hepatol, 2018, 8(1): 58-80. DOI: 10.1016/j.jceh.2017.12.001. |
| [22] |
CHIEN RN, KAO JH, PENG CY, et al. Taiwan consensus statement on the management of chronic hepatitis B[J]. J Formos Med Assoc, 2019, 118(1 Pt 1): 7-38. DOI: 10.1016/j.jfma.2018.11.008. |
| [23] |
Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B[J]. Clin Mol Hepatol, 2022, 28(2): 276-331. DOI: 10.3350/cmh.2021.0178. |
| [24] |
HUANG DQ, LI X, LE MH, et al. Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis B patients with indeterminate phase[J]. Clin Gastroenterol Hepatol, 2022, 20(8): 1803-1812. e5. DOI: 10.1016/j.cgh.2021.01.019. |
| [25] |
YAO K, LIU J, WANG J, et al. Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone[J]. J Viral Hepat, 2021, 28(7): 1025-1033. DOI: 10.1111/jvh.13511. |
| [26] |
|
| [27] |
SPRADLING PR, XING J, RUPP LB, et al. Distribution of disease phase, treatment prescription and severe liver disease among 1598 patients with chronic hepatitis B in the Chronic Hepatitis Cohort Study, 2006-2013[J]. Aliment Pharmacol Ther, 2016, 44(10): 1080-1089. DOI: 10.1111/apt.13802. |
| [28] |
Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (2022 version)[J]. Chin J Infect Dis, 2023, 41(1): 3-28. DOI: 10.3760/cma.j.cn311365-20230220-00050. |
DownLoad: